Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy
Zydus Lifesciences announced on Tuesday it is acquiring two biologics contract manufacturing facilities in California from US-based Agenus Inc for a total consideration of up to $125 million. The deal includes an upfront payment of $75 million, with the remaining $50 million to be paid over the following three years.
The Ahmedabad-based pharmaceutical firm said the acquisition will establish its presence in the rapidly-expanding global biologics contract development and manufacturing organization (CDMO) sector.
Zydus is also acquiring a 5.9% stake in Agenus for $16 million, through its wholly-owned subsidiary Zynext Ventures USA LLC, it said in an exchange filing on Tuesday.
The drugmaker has also entered into a licensing agreement with Agenus to commercialise its investigational Botensilimab (BOT) and Balstilimab (BAL) combination therapy in India and Sri Lanka.
Agenus is a clinical-stage immuno-oncology company committed to developing immune therapies against cancer.
The move to acquire biologics manufacturing facilities in the US aligns with Zydus' strategic focus on biologics as a key growth driver this year.
Also Read: Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial
"The acquisition will give Zydus a strategic foothold in the US for biologics manufacturing in the global hub for biotech innovation, California," managing director Sharvil Patel said in a statement. 'This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry," he added.
Additionally, the acquisition gives the company a stronger manufacturing presence in the US, amid ongoing uncertainties over potential American tariffs on pharmaceutical imports.
In the company's earnings call last month, Patel had said the company is evaluating opportunities for local manufacturing in the US. 'We have committed to making a good amount of investments in the US with our foray into specialty and other areas," he told investors.
Exclusive manufacturer to Agenus
Under the terms of the agreement, Zydus will acquire two modern biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California, for an upfront consideration of $75 million and contingent payment of $50 million to be paid over three years subject to achievement of certain revenue milestone.
The acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and a foothold in California, a leading global biotech hub. The move also enables Zydus to 'leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally," it said in the release.
Also Read: KKR provides $600 mn financing to Manipal Group to fuel its corporate expansion
The CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities.
As part of the transaction, Zydus will become the exclusive contract manufacturer for Agenus, and provide manufacturing services for the clinical and commercial supply of two identified Phase-3 ready immuno-oncology products - Botensilimab and Balstilimab.
Zydus will also have the first right of negotiation to manufacture any of the future pipeline products by Agenus.
Agenus reported a turnover of $103.46 million in 2024, according to the exchange filing.
Agenus' lead programme comprising Botensilimab and Balstilimab is a next-generation immunotherapy platform designed to strengthen and sustain the immune system's response against tumour cells. The platform, which is currently in advanced clinical trials, has demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and patients who have undergone neoadjuvant, or primary, therapy.
As part of the licensing agreement inked with Agenus, Zydus will be responsible for clinical development and regulatory approvals of the licensed products in India and Sri Lanka and will pay 5% royalty on net sales upon successful approval and commercialization.
Also Read: Young heirs take charge as Indian pharma firms plan succession
Zydus will expand the reach of the therapy within its initial indications, as well as drive its expansion into other high unmet need indications and earlier lines of treatment, including primary treatments, the company said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
20 minutes ago
- Time of India
OpenAI finds more Chinese groups using ChatGPT for malicious purposes
OpenAI is seeing an increasing number of Chinese groups using its artificial intelligence technology for covert operations, which the ChatGPT maker described in a report released Thursday. While the scope and tactics employed by these groups have expanded, the operations detected were generally small in scale and targeted limited audiences, the San Francisco-based startup said. Since ChatGPT burst onto the scene in late 2022, there have been concerns about the potential consequences of generative AI technology , which can quickly and easily produce human-like text, imagery and audio. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 2 Simple Profitable Strategies That Can Make You 5K Per Day thefutureuniversity Learn More OpenAI regularly releases reports on malicious activity it detects on its platform, such as creating and debugging malware, or generating fake content for websites and social media platforms. In one example, OpenAI banned ChatGPT accounts that generated social media posts on political and geopolitical topics relevant to China, including criticism of a Taiwan-centric video game, false accusations against a Pakistani activist, and content related to the closure of USAID. Live Events Some content also criticised US President Donald Trump 's sweeping tariffs, generating X posts, such as "Tariffs make imported goods outrageously expensive, yet the government splurges on overseas aid. Who's supposed to keep eating?". Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories In another example, China-linked threat actors used AI to support various phases of their cyber operations , including open-source research, script modification, troubleshooting system configurations, and development of tools for password brute forcing and social media automation. A third example OpenAI found was a China-origin influence operation that generated polarized social media content supporting both sides of divisive topics within U.S. political discourse, including text and AI-generated profile images. China's foreign ministry did not immediately respond to a Reuters request for comment on OpenAI's findings. OpenAI has cemented its position as one of the world's most valuable private companies after announcing a $40 billion funding round valuing the company at $300 billion.
Time of India
20 minutes ago
- Time of India
Uber appoints Palo Alto CEO Nikesh Arora to board
Uber has appointed Palo Alto Networks chief executive Nikesh Arora to its board, according to a filing with the Securities and Exchange Commission. He will serve on the Nominating and Governance Committee and Compensation Committee. Arora, 57, has been the Chairman of the board and chief executive officer (CEO) of cybersecurity firm Palo Alto Networks since June 2018. Prior to joining Palo Alto Networks, he was an angel investor from 2016 to 2018. Before that, he worked with SoftBank Group Corp in various senior capacities from 2014 to 2017. Notably, SoftBank made significant investments in Uber in 2018 and 2019, becoming its largest shareholder at one point. SoftBank sold a third of its stake in the ride hailing platform in 2021 and offloaded the rest between April and July 2022. Arora was also one of the top candidates being considered as successors to former Uber CEO Travis Kalanick after he resigned in June 2017. The job went to Dara Khosrowshahi . Prior to SoftBank, from December 2004 through July 2014, Arora held multiple senior leadership operating roles at Google , Inc., including serving as senior vice president and chief business officer, from January 2011 to June 2014. The Palo Alto CEO also serves on the board of Compagnie Financiere Richemont S.A., a public Switzerland-based luxury goods holding company. He has previously served on the boards of insurance company Aviva PLC, Indian telecom major Bharti Airtel , US communications services company Sprint Corp, global FMCG company Colgate-Palmolive Company, SoftBank, and Yahoo! Japan. 'Nikesh is one of the technology industry's great executives: a strategic and disciplined operator, and a fierce competitor. We're thrilled to welcome him to the board and look forward to his contributions as we continue to advance our long-term strategy,' said Uber chief executive officer Khosrowshahi. As an Uber director, Arora will receive a $60,000 annual cash retainer and restricted stock units with a fair value of $300,000, the SEC filing said.
Time of India
31 minutes ago
- Time of India
No rollback of satcom recommendations, government to decide: Trai official
NEW DELHI: The telecom regulator's views were based on an extensive consultative process involving divergent views from multiple stakeholders, and could not be reconsidered, while it's for the government to take a final call, a senior regulatory official said. "We have duly followed the extensive and transparent consultative process with multiple stakeholders sharing divergent views. It is for the government to decide," a Trai official on the conditions of anonymity told ETTelecom, adding that "a level-playing field is out of question" in the current context. "Satellite communications or satcom is a complementary service to terrestrial network providers, with no question of a level playing field between the two. The ₹500 per subscription charge is aimed at enhancing coverage and encouraging space broadband providers to offer services across the country's rural landscape." Early this week, Delhi-based Cellular Operators Association of India (COAI), which represents Reliance Jio, Bharti Airtel and Vodafone Idea, in a letter to the Department of Telecommunications (DoT) said that the watchdog has "underestimated the potential capacities of satellite networks" while possibly overstating those of terrestrial networks. "Incorrect assumptions have led to unjustifiably low spectrum charges for satellite services relative to terrestrial networks," COAI director general SP Kochhar added in his letter to DoT secretary Neeraj Mittal. However, Trai, citing a huge capacity variation between the two sets of players, strongly defended its move. "In our recommendation, we have clearly brought out that there is no case of level-playing field between the satellite service providers and terrestrial service operators because of the huge difference of capacity between them," the senior official said. "So, the capacity of a typical satcom service provider in terms of the internet capacity, is of the order of maybe 0.5 to 1 or 2 percent of the capacity of a typical large terrestrial service provider. So there is no question of level-playing field. It is a complimentary service." The telco lobby group said that the planned capacity of Elon Musk-owned Starlink and Jeff Bezos led-Amazon Kuiper are expected to surpass the current capacity of Reliance Jio, Bharti Airtel and Vodafone Idea combined. The idea behind prescribing ₹500 additional charge for urban subscription, according to the official, was to "encourage and nudge satellite service providers" to offer services in the country's rural areas as well. "They can divert their capacity to urban areas to some extent, but we want to nudge them to focus on rural and remote regions. This is the background under which the recommendation was made," he added. Meanwhile, satcom players backed the regulator, and said Trai's views were aimed at bringing affordable space broadband services to bridge the existing digital divide. Telecom watchdog recommended administrative allocation of satcom spectrum with a fee pegged amounting to 4% of adjusted gross revenue (AGR), for a five-year term, and that can be extended by another 2 years. The 4% AGR fee applies to both geostationary and non-geostationary satellite operators. Trai's proposal to subsidise user terminals for satellite operators through the Digital Bharat Nidhi (DBN) fund further tilts the level playing field against the terrestrial operator, especially given that a majority of the DBN levy is contributed by telcos, Kochhar added in his letter. The regulatory official said that it has recommended facilitating a target set of users that the government might want to support in unserved or rural and remote areas. "The government can consider subsidising the cost of the terminal. It is for the government to make a decision based on a targeted group or category of users." Lately, the activity in India's nascent space-led communication services sector has intensified following the entry of spaceflight company SpaceX's satellite network Starlink, partnering with Mukesh Ambani's Reliance Jio and Sunil Mittal-driven Bharti Airtel.
